Outcome After Acute Ischemic Stroke Treatment During Covid-19 Outbreak in South-East Tuscany
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: During Covid-19 pandemic, the Italian National Healthcare Service has faced increasing pressure, especially in Northern Italy. Even in less-affected regions, such as Tuscany, the changes in the healthcare system to prevent Covid-19 spread resulted in difficulty in treating time-dependent disorders like ischemic stroke rapidly.
OBJECTIVE: The aim of our study was to assess the outcome after acute ischemic stroke treatments during the Covid-19 spread in comparison with a similar period of the previous year in Siena-Hospital (Hub center in the South-East Tuscany).
METHODS: We enrolled all patients admitted to Siena-Hospital for ischemic stroke and submitted them to acute treatments (intravenous and/or mechanical thrombolysis) between February 21st and May 18th, 2020 (study group, n:38) and compared the results with ischemic strokes acutely treated in a similar period in 2019 (control group, n:39). The modified Rankin scale score was assessed at 90 days to evaluate a 3-month clinical outcome.
RESULTS: In the study group, the time from symptoms onset to hospital arrival and the door-to-groin puncture time were significantly more prolonged than in the control group. In moderate-severe strokes, the 3-month mortality was significantly higher in the study group (31% vs. 6%; p=0.01), and the number of patients with poor functional outcomes was significantly higher in the study group (73% vs. 44%; p=0.03).
CONCLUSION: During the lockdown period due to Covid-19 pandemic, patients with acute ischemic stroke had a worse prognosis. These findings suggest the need to improve the health system organization to guarantee an appropriate treatment during the pandemic, including the patients that are not affected by Covid-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Cardiovascular & hematological disorders drug targets - 21(2021), 3 vom: 01., Seite 179-184 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Acampa, Maurizio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alteplase |
|---|
| Anmerkungen: |
Date Completed 14.01.2022 Date Revised 14.01.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871529X21666210927094058 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33121248X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33121248X | ||
| 003 | DE-627 | ||
| 005 | 20231225212951.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871529X21666210927094058 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1104.xml |
| 035 | |a (DE-627)NLM33121248X | ||
| 035 | |a (NLM)34579640 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Acampa, Maurizio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcome After Acute Ischemic Stroke Treatment During Covid-19 Outbreak in South-East Tuscany |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.01.2022 | ||
| 500 | |a Date Revised 14.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: During Covid-19 pandemic, the Italian National Healthcare Service has faced increasing pressure, especially in Northern Italy. Even in less-affected regions, such as Tuscany, the changes in the healthcare system to prevent Covid-19 spread resulted in difficulty in treating time-dependent disorders like ischemic stroke rapidly | ||
| 520 | |a OBJECTIVE: The aim of our study was to assess the outcome after acute ischemic stroke treatments during the Covid-19 spread in comparison with a similar period of the previous year in Siena-Hospital (Hub center in the South-East Tuscany) | ||
| 520 | |a METHODS: We enrolled all patients admitted to Siena-Hospital for ischemic stroke and submitted them to acute treatments (intravenous and/or mechanical thrombolysis) between February 21st and May 18th, 2020 (study group, n:38) and compared the results with ischemic strokes acutely treated in a similar period in 2019 (control group, n:39). The modified Rankin scale score was assessed at 90 days to evaluate a 3-month clinical outcome | ||
| 520 | |a RESULTS: In the study group, the time from symptoms onset to hospital arrival and the door-to-groin puncture time were significantly more prolonged than in the control group. In moderate-severe strokes, the 3-month mortality was significantly higher in the study group (31% vs. 6%; p=0.01), and the number of patients with poor functional outcomes was significantly higher in the study group (73% vs. 44%; p=0.03) | ||
| 520 | |a CONCLUSION: During the lockdown period due to Covid-19 pandemic, patients with acute ischemic stroke had a worse prognosis. These findings suggest the need to improve the health system organization to guarantee an appropriate treatment during the pandemic, including the patients that are not affected by Covid-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Ischemic stroke | |
| 650 | 4 | |a alteplase | |
| 650 | 4 | |a mechanical thrombolysis | |
| 650 | 4 | |a thrombolysis | |
| 650 | 4 | |a treatment outcome. | |
| 700 | 1 | |a Peresso, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Lazzerini, Pietro Enea |e verfasserin |4 aut | |
| 700 | 1 | |a Domenichelli, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Guideri, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Tassi, Rossana |e verfasserin |4 aut | |
| 700 | 1 | |a Dami, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Marconi, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Iannelli, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Linoli, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Peppoloni, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Nocentini, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Gallerini, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Cartocci, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Bracco, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Martini, Giuseppe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular & hematological disorders drug targets |d 2006 |g 21(2021), 3 vom: 01., Seite 179-184 |w (DE-627)NLM163039259 |x 2212-4063 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:3 |g day:01 |g pages:179-184 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871529X21666210927094058 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 3 |b 01 |h 179-184 | ||